Share |

JDRF International

 2 Corporate Park, #106
 Irvine, CA 92606
[P] (949) 553-0363
[F] (949) 553-8813
www.jdrf.org
www.walk.jdrf.org
[email protected]
Cathy Sleva
FOUNDED: 1970
INCORPORATED: 1970
 Printable 1 Page Summary
 Printable Profile
Organization DBA JDRF
Juvenile Diabetes Research Foundation
Former Names Juvenile Diabetes Research Foundation (2011)
Organization received a competitive grant from the community foundation in the past five years No
Employer Identification Number 23-1907729 00001

Summary


Mission StatementMORE »

JDRF's mission is accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications. It is also committed to developing new and better treatments that improve the lives of people with type 1 diabetes in the near term and keep them healthy while we advance toward a cure. JDRF’s promise is to progressively remove the impact of T1D from the lives of those living with the disease until it is no longer a threat to them or their families.

Mission Statement

JDRF's mission is accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications. It is also committed to developing new and better treatments that improve the lives of people with type 1 diabetes in the near term and keep them healthy while we advance toward a cure. JDRF’s promise is to progressively remove the impact of T1D from the lives of those living with the disease until it is no longer a threat to them or their families.

FinancialsMORE »

Fiscal Year 2017
Projected Expenses $1,106,711.00
Projected Revenue $2,499,643.00

ProgramsMORE »

  • Artificial Pancreas
  • Complications
  • Encapsulation
  • Smart Insulin
  • Restoration
  • Prevention

Revenue vs. Expense ($000s)

Expense Breakdown 2015 (%)

Expense Breakdown 2014 (%)

Expense Breakdown 2013 (%)

For more details regarding the organization's financial information, select the financial tab and review available comments.


Overview


Mission Statement

JDRF's mission is accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications. It is also committed to developing new and better treatments that improve the lives of people with type 1 diabetes in the near term and keep them healthy while we advance toward a cure. JDRF’s promise is to progressively remove the impact of T1D from the lives of those living with the disease until it is no longer a threat to them or their families.

Background Statement

JDRF was founded in 1970 by parents of children with type 1 diabetes. Today, volunteers at JDRF's more than 100 locations worldwide remain the driving force behind its success in advancing research toward curing, treating, and preventing T1D.
 
Since its founding in 1970, JDRF has awarded more than $1.6 billion to T1D research. More than 80% of JDRF's expenditures directly support research and research-related education.

Impact Statement

JDRF’s ultimate goal is a world without type 1 diabetes. As it makes progress toward this goal, JDRF is also working to deliver new therapies that keep those with T1D healthier and safer in the near-term.
 
First, JDRF wants to substantially lessen the daily impact and dangers of life with T1D through new treatments such as a closed-loop artificial pancreas system and smart insulin, as well as comprehensive treatment and prevention for complications. Then, JDRF seeks to completely remove T1D from people’s lives, returning them to normalcy through therapies such as implantable encapsulated islet cells and beta cell regeneration. Finally, JDRF aims to remove the threat of T1D for everyone in the future
through primary and secondary prevention.

JDRF is driving research across the entire research pipeline, from discovery in the laboratory to delivery of new technology and treatments to patients.It is collaborating with public, academic and corporate partners to expedite delivery of real-world solutions to T1D patients and families. JDRF is currently providing more than $100 million per year to fund T1D research and achieve its goal of turning Type One into Type None.

Needs Statement

JDRF will require substantial annual investments to reach our long-term goal of a world without type 1 diabetes. The path forward to this goal is an expensive one.
 
Today, JDRF has $530 million at work around the world advancing its goals. But it is not enough.Increased funding is essential. Clinical trials and clinical development (including proof of effectiveness and safety in humans) is increasingly costly. The gap between what JDRF has and what it needs is significant. JDRF requires substantial help to bridge that gap and provide the future we must have for people with T1D.

CEO Statement

JDRF is the leading global organization focused on Type 1 diabetes (T1D) research.  Our goal is to progressively remove the impact of T1D from people's lives until we achieve a world without it.  JDRF collaborates with a wide spectrum of partners and is the only organization with scientific resources, regulatory influence and a working plan to bring life-changing therapies from the lab to the community. 

Board Chair Statement

“It is an honor to assume the role as JDRF’s President and CEO,” said Rapp. “JDRF is a unique organization with a powerful mission. I look forward to building on the strong foundation Jeffrey Brewer has created. I am excited to lead our incredibly talented team as we work together to deliver life changing treatments, and eventually a cure, to those living with T1D today, on our way to preventing the disease for generations to come. In the end, I know that we will succeed because the passion, determination, and dedication of our donors and our army of volunteers across the world will accept nothing less.”

Rapp has been involved with JDRF since his son, Turner, was diagnosed with the disease in 2004. He has served on the JDRF IBOD since 2010. In addition to that role, he has served as Research Chair and as a member of the Research Committee, the Lay Review Committee, the Strategic Alliances Committee, the Development Committee, and the Advocacy Committee.



Other Ways to Donate/Volunteer

You can donate to JDRF in a variety of ways.  Checks can be mailed to the Corporate Park address, donations may be taken over the phone and online, and recurring donations can be set up through our National office.  We also have many volunteer opportunities, mostly involving our events - Walk, Gala, and Golf.  However, we have volunteer opportunities doing office work and advocacy. Children up through age 18 can also apply to be Youth Ambassadors.

Geographic Area Served

International
Central Orange County
West Orange County
South Orange County
North Orange County
Central Orange County
West Orange County
South Orange County
North Orange County
JDRF is the leading global organization exclusively focused on type 1 diabetes (T1D) research. It partners with academia, foundations, industry, governments, regulators, and insurers throughout the world, in a global, coordinated effort with JDRF is at the center.

JDRF is the only global organization with a strategic plan to bring a continuous flow of life-changing therapies and, ultimately, a cure for T1D.  JDRF is headquartered in the U.S. and has affiliate offices in seven additional countries throughout the world.

Organization Categories

  1. Medical Research - Specifically Named Diseases Research
  2. Diseases Disorders & Medical Disciplines - Specifically Named Diseases
  3. Medical Research - Medical Research NEC

--

Programs


Artificial Pancreas

Artificial pancreas (AP) systems will be the most revolutionary advance in diabetes care since the discovery of insulin.  Like the body's pancreas, AP systems will react to rising blood-glucose levels by combing monitoring technology with insulin pumps to provide the right amount of insulin at the right time.  Not only will the AP systems result in much tighter control, lowering the risk of health complications later in life, they will also reduce the constant worry about blood-sugar levels and what must be done to manage them.

Budget  $50,000,000.00
Category  Medical Research, General/Other Diabetes Research
Population Served People/Families of People with Health Conditions US& International General/Unspecified
Program Short-Term Success   Today we are drawing closer to seeing AP systems come to market. In late 2012, the FDA released final guidance for device makers to secure approval and commercialize the system
Program Long-Term Success   Reaching our ultimate goal of turning Type One into Type None
Program Success Monitored By  Outpatient trials of first generation  systems are already under way. 
Examples of Program Success   

Complications

Despite significant advances in blood sugar (blood glucose) level monitoring and insulin therapy, people with diabetes still spend significant portions of the day with too high levels of blood glucose, placing them at risk for the development of diabetes complications.

Budget  $50,000,000.00
Category  Diseases, Disorders & Medical Disciplines, General/Other Diabetes
Population Served US& International General/Unspecified
Program Short-Term Success   We are currently working on research that reverses diabetic retinopathy.
Program Long-Term Success   Ultimately there would be NO complications from diabetes.
Program Success Monitored By    We are currently working on research that reverses diabetic retinopathy.
Examples of Program Success  --

Encapsulation

Encapsulation describes a therapy where a pouch composed of beta cells or islet cells, surrounded by a protective barrier, is implanted into the body. The barrier keeps the newly implanted cells alive by hiding them from the immune system, providing a safe environment where they can function normally. The cells constantly assess the amount of glucose in the blood and release exactly the correct amount of insulin. And unlike islet transplants, no immunosuppressive drugs are required.


Budget  $25,000,000.00
Category  Medical Research, General/Other Diabetes Research
Population Served General/Unspecified US& International
Program Short-Term Success   

In efforts to reach our ultimate goal of a world without T1D, JDRF has been a leader in driving encapsulation research forward. In fact, we have already supported some of the earliest human trials to evaluate select encapsulation strategies. Specifically, through our industry partnerships, JDRF is testing the ability of encapsulated pig islets to reverse severe hypoglycemic unawareness in humans. And we’re helping to advance encapsulated stem cell precursors to beta cells into human testing.

Program Long-Term Success 

Encapsulated cell therapy has the potential to virtually eliminate the relentless daily management burden for those living with T1D: no need for multiple daily insulin injections or pump therapy, no more constant blood testing and no more carb counting. People with T1D would just go about their daily lives for extended periods of time as if they didn’t even have the disease.


 
Program Success Monitored By   

In the years ahead, JDRF will advance a number of encapsulation approaches to human trials as quickly as possible to determine which are the most promising, effective, and safe to deliver to people living with T1D.

Examples of Program Success  --

Smart Insulin


Smart insulin is a form of insulin that circulates in the bloodstream and turns on when it’s needed to lower blood sugars and off when blood sugars are at safe levels.


Budget  $25,000,000.00
Category  Medical Research, General/Other Diabetes Research
Population Served General/Unspecified
Program Short-Term Success   

Moreover, by improving overall blood-glucose controls, the risks of life-threatening complications would sharply diminish, leading to longer, healthier lives.

Program Long-Term Success   

Eliminating virtually all of the daily burdens associated with mechanically managing the disease would profoundly enhance and simplify the lives of people with T1D

Program Success Monitored By   First the National Institutes of Health provided initial funding, using funds appropriated by Congress in response to JDRF’s advocacy efforts. Then, JDRF added its funding to take it to the next stage. And in 2010, the pharmaceutical company Merck acquired SmartCells. The evolution of SmartCells is powerful validation of JDRF’s strategy to support early stage therapy development to draw the capital and commercial know-how of major drug and biotech manufacturers to the T1D field
Examples of Program Success  --

Restoration


A full biological cure is the ultimate and permanent solution to all the complexity and problems of T1D. The delivery of that cure would mean the fulfillment of JDRF’s vision of a world without T1D


Budget  $65,000,000.00
Category  Medical Research, General/Other Diabetes Research
Population Served General/Unspecified
Program Short-Term Success   

JDRF researchers have already demonstrated that the body has the ability to grow new beta cells in certain situations, such as pregnancy. Even those with long-term T1D have shown they can still grow beta cells. Now, JDRF is advancing a number of approaches to trigger the body’s ability to do the same in all those with T1D. JDRF is also exploring how to reprogram other cells in the body to become beta cells. And we’re exploring ways the pancreas can become its own source of new beta cells.

Program Long-Term Success   

But restoring the body’s ability to create new beta cells while simultaneously preventing recurrence of the deadly autoimmune attack is the greatest challenge yet. We’re working to accomplish something that no one else has: permanently turning off an autoimmune response. We’re confident it can be done, and JDRF is leading the way in funding research aimed at this historic goal.

Program Success Monitored By   

At the same time, we’ve discovered a number of suspected triggers associated with the onset of T1D, including certain viruses. This has opened the door to the development of new approaches that would prevent the destructive immune system response in T1D. This might take the form of a viral vaccine, similar to the polio vaccine, or it might be a therapy similar to an allergy shot, which would educate or reeducate the body’s immune system not to initiate an attack on the beta cells.

Examples of Program Success  --

Prevention


Preventing people from ever developing T1D is the ultimate answer. Consider polio or smallpox—neither have been cured, but effective vaccines have largely eradicated these diseases from our society.


Budget  $25,000,000.00
Category  Medical Research, General/Other Diabetes Research
Population Served General/Unspecified
Program Short-Term Success   

Secondary prevention is focused on finding ways to prevent insulin dependence in individuals at risk or where the autoimmune attack on beta cells has already begun.

Program Long-Term Success   

Primary prevention means literally preventing the autoimmune attack so people never develop T1D at all.


Program Success Monitored By   

Both primary and secondary prevention approaches show considerable promise, but critical knowledge gaps remain. We need to make progress to screen for the risk, susceptibility, and onset of the autoimmune attack. We need to better understand how the disease progresses to allow us to develop tailored ways to intervene at various early stages to prevent insulin dependence. All this requires more funding. It will take tens of millions of dollars to continue this research and make prevention a reality. With your support, together we can change Type One into Type None.

Examples of Program Success  --

Management


CEO/Executive Director Ms. Cathy Sleva
CEO Term Start Dec 2013
CEO Email [email protected]
CEO Experience

STRENGTHS

·         Twenty-five years of project, program, and nonprofit management experience

·         Have been instrumental in raising over $20,000,000 during thirteen years as a development professional

·         Strong relationship-building and fiscal management skills

·         Advanced formal training in Management, with an emphasis in Marketing

·         Outstanding organizational and communication skills

 

RELEVANT EXPERIENCE

          JDRF, Orange County Chapter, Executive Director

·         Manage Orange County Chapter and Inland Empire Branch with a combined $3+ million fundraising budget and 7 employees.

·         Work with Board members to leverage relationships, resulting in increased funding for JDRF.

·         Work with Committee Chairs to update Chapter’s strategic plan.

·         In concert with Regional Director, devise yearly budget and make sure staff understands their fundraising goals.

·         Make sure staff has relevant training and stays up to date on policies and procedures.

EDUCATION

Master of Business Administration, December 2001, University of North Carolina at Charlotte

 

Bachelor of Arts in Speech Communications, June 1988,  University of Georgia, Athens

 PROFESSIONAL AFFILIATIONS/TRAINING

·         Member, Association of Fundraising Professionals, Atlanta and Orange County Chapters

·         Dale Carnegie Corporate Training

·         Media Training from MSLGroup – Atlanta

·         The Fundraising School at The Center on Philanthropy at Indiana University - Planned Giving:  Getting the Proper Start

·         The Fundraising School at The Center on Philanthropy at Indiana University - Principles and Techniques of Fundraising

Former CEOs and Terms

Name Start End
Linda Riley -- --

Senior Staff

Name Title Experience/Biography
Ms. Michelle Popoff Senior Development & Outreach Mgr. --

Awards

Award Awarding Organization Year
Forbes Top 5 All Star Charities Forbes 2012

Affiliations

Affiliation Year
-- --

External Assessments and Accreditations

External Assessment or Accreditation Year
-- --

Collaborations

--

Staff Information

Number of Full Time Staff 6
Number of Part Time Staff 0
Number of Volunteers 300
Number of Contract Staff 0
Staff Retention Rate % 83%
Staff Professional Development Yes

Staff Demographics

Ethnicity African American/Black: 0
Asian American/Pacific Islander: 0
Caucasian: 5
Hispanic/Latino: 0
Native American/American Indian: 0
Other: --
Other (if specified): --
Gender Female: 5
Male: 0
Not Specified --

Plans & Policies

Organization has Fundraising Plan? Yes
Organization has Strategic Plan? Yes
Years Strategic Plan Considers 5
Management Succession Plan No
Organization Policies And Procedures Yes
Business Continuity of Operations Plan Yes

Risk Management Provisions

Nondiscrimination Policy Yes
Whistle Blower Policy Yes
Document Destruction Policy Yes
Directors and Officers Insurance Policy Yes

Reporting and Evaluations

Management Reports to Board? Yes
CEO Formal Evaluation and Frequency Yes Semi-Annually
Senior Management Formal Evaluation and Frequency Yes Semi-Annually
Non Management Formal Evaluation and Frequency Yes Semi-Annually

Government Licenses

--

CEO Comments

--

Foundation Comments

--

Governance


Board Chair Mr. John Stoner
Board Chair Company Affiliation Stoner Fox Law Group
Board Chair Term July 2016 - June 2018
Board Co-Chair --
Board Co-Chair Company Affiliation --
Board Co-Chair Term -

Board Members

Name Company Affiliations Status
Michael Adamson HR Consultant Voting
Analisa Albert Community Volunteer Voting
Mary Allen Community Volunteer Voting
Erik Anderson Aviation Capital Group Voting
Marsha Baker Retired Voting
Chris Barnett BBSI Voting
Rose Bauss Toyota Voting
Judy Brandt Fox & Company Voting
Stacie Brewster Community Volunteer Voting
Janet Cheetham Consultant Voting
Kevin Coleman Canon Business Solutions Voting
Jennifer Condas Community Volunteer Voting
James Cueva Jaeger-LeCoultre Voting
Lauri Delson Herbert Family Program at Hoag Hospital Voting
Frank Deni Retired Voting
Cindy Dreyer Community Volunteer Voting
Brian Giovannone ProSport Physical Therapy --
Carl Hattermann UBS Voting
Julie Hellmers Community Volunteer Voting
Karen Hill Consultant Voting
Christina Jenkins Community Volunteer Voting
Norm Kallan Retired Voting
Lori Kenyon Farley BNY Mellon Voting
Jeff Klein Boston Group Voting
Michael LaBriola Haney Labriola Voting
Robert Loewen Retired Voting
Laura Marroquin Naples Rib Co. Voting
Cindi Morales Community Volunteer Voting
Tom Porter Marquee Staffing Voting
Linda Robertson private practice Voting
J.D. Shafer Irvine Company Voting
John Stoner Stoner Fox Law Group Voting
Mark Wilson Tarbox Group Voting
Ann Winthrop Community Volunteer Voting

Constituent Board Members

Name Company Affiliations Status
-- -- --

Youth Board Members

Name Company Affiliations Status
-- -- --

Additional Board Members and Affiliations

Name Company Affiliations Status
-- -- --

Board Demographics

Ethnicity African American/Black: 0
Asian American/Pacific Islander: 1
Caucasian: 31
Hispanic/Latino: 3
Native American/American Indian: 0
Other: 0
Other (if specified): 0
Gender Female: 18
Male: 16
Not Specified 0

Board Information

Board Term Lengths 2
Board Term Limits 3
Board Meeting Attendance % 60%
Written Board Selection Criteria Under Development
Written Conflict Of Interest Policy Yes
Percentage of Monetary Contributions 100%
Percentage of In-Kind Contributions 40%
Board Orientation Yes

CEO Comments

While the information contained in this report details our local, Chapter Board, we also have an International Board.  More information on our International Board can be found here:  http://oc.jdrf.org/about-jdrf/leadership/.

Foundation Comments

--

Standing Committees

  • Board Development / Board Orientation
  • Community Outreach / Community Relations
  • Development / Fund Development / Fund Raising / Grant Writing / Major Gifts
  • Executive
  • Nominating
  • Special Events (Golf Tournament, Walk / Run, Silent Auction, Dinner / Gala)

Financials


Revenue vs. Expense ($000s)

Expense Breakdown 2015 (%)

Expense Breakdown 2014 (%)

Expense Breakdown 2013 (%)

Fiscal Year July 01, 2016 to June 30, 2017
Projected Revenue $2,499,643.00
Projected Expenses $1,106,711.00
Form 990s

2015 990

2014 Form 990

2013 FY13 990

2012 FY12 990

2011 FY11 990

Audit Documents

2015 Audit

2014 audit

2013 Audit

IRS Letter of Exemption

IRS Letter of Determination

Prior Three Years Total Revenue and Expense Totals

Fiscal Year 2015 2014 2013
Total Revenue $204,366,782 $219,880,522 $206,223,491
Total Expenses $189,479,405 $215,705,720 $209,495,741

Prior Three Years Revenue Sources

Revenue By Revenue Source
Fiscal Year 2015 2014 2013
Foundation and
Corporation Contributions
$196,804,267 $77,389,865 $55,247,379
Government Contributions $0 $0 $0
    Federal -- -- --
    State -- -- --
    Local -- -- --
    Unspecified -- $0 --
Individual Contributions -- -- --
Indirect Public Support -- $4,650,283 $4,406,173
Earned Revenue -- $0 --
Investment Income, Net of Losses $6,524,427 $1,660,898 $9,200,541
Membership Dues -- $0 --
Special Events -- $128,028,787 $122,740,842
Revenue In-Kind -- $14,685,688 $13,616,269
Other $1,027,088 $1,086,957 $1,012,287

Prior Three Years Expense Allocations

Expense By Type
Fiscal Year 2015 2014 2013
Program Expense $75,084,432 $171,195,390 $169,806,654
Administration Expense $74,149,309 $17,938,120 $15,986,558
Fundraising Expense -- $26,572,210 $23,702,529
Payments to Affiliates $40,245,664 $0 --
Total Revenue/Total Expenses 1.08 1.02 0.98
Program Expense/Total Expenses 40% 79% 81%
Fundraising Expense/Contributed Revenue 0% 13% 13%

Prior Three Years Assets and Liabilities

Assets and Liabilities
Fiscal Year 2015 2014 2013
Total Assets $197,093,128 $207,538,339 $196,040,120
Current Assets -- $64,243,759 $52,170,452
Long-Term Liabilities $133,197,854 $2,411,967 $0
Current Liabilities -- $161,265,000 $162,509,815
Total Net Assets $63,895,274 $43,861,372 $33,530,305

Short Term Solvency

Fiscal Year 2015 2014 2013
Current Ratio: Current Assets/Current Liabilities nan 0.40 0.32

Long Term Solvency

Fiscal Year 2015 2014 2013
Long-term Liabilities/Total Assets 68% 1% 0%
Endowment Value $0.00
Spending Policy N/A
Percentage(If selected) --
Are you currently in a Capital Campaign? No
Capital Campaign Purpose N/A
Campaign Goal --
Capital Campaign Dates -
Capital Campaign Raised-to-Date Amount --
Capital Campaign Anticipated in Next 5 Years? No

CEO Comments

--

Foundation Comments

Summary financial data is per the Form 990s and consultation with the organization. Foundation/corporate and individual contributions are combined under Foundation and Corporation Contributions.

Documents


Other Documents

No Other Documents currently available.